Alpha-melanocyte-stimulating hormonelike immunoreactivity is increased in cerebrospinal fluid of patients with Parkinson's disease.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Archives of Neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 2847695
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anatomical evidence for interactions between catecholamine- and adrenocorticotropin-containing neurons.

  1986cited by this paper
• Further characterization of the extra-arcuate alpha-melanocyte stimulating hormone-like material in hypothalamus: biochemical and anatomical studies.

  1986cited by this paper
• Pro-opiomelanocortin peptides in the human hypothalamus: comparative study between normal subjects and Parkinson patients.

  1985cited by this paper
• β‐Endorphin cerebrospinal fluid decrease in untreated parkinsonian patients

  1985cited by this paper
• Long-term haloperidol treatment elevates beta-endorphin levels in the intermediate pituitary but not in rat brain.

  1985cited by this paper
• Effects of neuroleptic drugs on brain beta-endorphin immunoreactivity.

  1985cited by this paper
• Human brain glucose utilization and cognitive function in relation to age

  1984cited by this paper
• Biochemistry of the hypothalamus in Parkinson's disease

  1984cited by this paper
• Cerebral glucose utilization, as measured with positron emission tomography in 21 resting healthy men between the ages of 21 and 83 years.

  1983cited by this paper
• Effect of dopaminergic drugs on hypothalamic and pituitary immunoreactive beta-endorphin concentrations in the rat.

  1983cited by this paper
• ACTH 1-24 and lysine vasopressin selectively activate dopamine synthesis in frontal cortex.

  1982cited by this paper
• Postural asymmetry and movement disorder after unilateral microinjection of adrenocorticotropin 1-24 in rat brainstem.

  1982cited by this paper
• The opiomelanotropinergic neuronal and endocrine systems.

  1982cited by this paper
• Release of alpha-melanocyte stimulating hormone into rat and human cerebrospinal fluid in vivo and from rat hypothalamus slices in vitro.

  1981cited by this paper
• Evidence that N-acetylation regulates the behavioral activity of alpha-MSH in the rat and human central nervous system.

  1981cited by this paper
• alpha-MSH in rat brain: occurrence within and outside of beta-endorphin neurons.

  1980cited by this paper
• Plasma and cerebrospinal fluid alpha-MSH levels in the rat after hypophysectomy and stimulation of pituitary alpha-MSH secretion.

  1979cited by this paper
• Intracerebral adrenocorticotropic hormone mediates novelty-induced grooming in the rat.

  1979cited by this paper
• Release of immunoreactive alpha-MSH by synaptosome-enriched fractions of homogenates of hypothalami.

  1979cited by this paper
• Identification, characterization and stereotaxic mapping of intraneuronal alpha-melanocyte stimulating hormone-like immunoreactive peptides in discrete regions of the rat brain.

  1979cited by this paper
• A SUBCELLULAR POOL OF HYPO‐OSMOTICALLY RESISTANT PARTICLES CONTAINING THYROTROPIN RELEASING HORMONE, α‐MELANOCYTE STIMULATING HORMONE, AND LUTEINIZING HORMONE RELEASING HORMONE IN THE RAT HYPOTHALAMUS

  1978cited by this paper
• The hypothalamus in parkinson disease

  1978cited by this paper
• Peptide hormones and central dopamine neuron systems.

  1977cited by this paper
• ACTH-induced excessive grooming involves brain dopamine.

  1977cited by this paper
• Neurochemical responses of mice to ACTH and lysine vasopressin.

  1976cited by this paper
• Parkinson's disease: Distribution of Lewy bodies and monoamine neuron system

  1976cited by this paper
• Glucose intolerance in Parkinson's disease.

  1974cited by this paper
• Hypothalamic releasing factors and Parkinson disease.

  1974cited by this paper
• Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy.

  1974cited by this paper
• Melanocyte-stimulating hormone and parkinsonism.

  1973cited by this paper
• Orthostatic hypotension in Parkinson's disease.

  1972cited by this paper
• Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.

  1972cited by this paper
• Effect of L-dopa on seborrhoea of parkinsonism.

  1970cited by this paper
• Induction of Sexual Excitement by the Action of Adrenocorticotrophic Hormone in Brain

  1969cited by this paper
• Parkinsonism

  1967cited by this paper
• Two cases of accidental hypothermia in Parkinson's disease with unusual E.E.G. findings.

  1966cited by this paper
• INFLUENCE OF ANTERIOR PITUITARY ON AVOIDANCE LEARNING AND ESCAPE BEHAVIOR.

  1964cited by this paper

• New insights underlying the early events of dopaminergic dysfunction in Parkinson’s Disease

  2023influential citation
• Review of the role of the endogenous opioid and melanocortin systems in the restless legs syndrome

  2023cites this paper
• Concussive head injury exacerbates neuropathology of sleep deprivation: Superior neuroprotection by co-administration of TiO2-nanowired cerebrolysin, alpha-melanocyte-stimulating hormone, and mesenchymal stem cells.

  2020cites this paper
• The alpha‐melanocyte‐stimulating hormone acts as a local immune homeostasis factor in experimental allergic asthma

  2019cites this paper
• α-Melanocyte Stimulating Hormone as a Potential Therapy for Alzheimer`s Disease.

  2016cites this paper
• Parkinson’s disease-associated melanin steal

  2014cites this paper
• Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

  2014cites this paper
• Melanocortins as innovative drugs for ischemic diseases and neurodegenerative disorders: established data and perspectives.

  2013cites this paper
• Activation of the proopiomelanocortin gene with ketoconazole as a treatment for Parkinson's disease: a new hypothesis.

  2008cites this paper
• Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease.

  2007cites this paper
• Is seborrhea a sign of autonomic impairment in Parkinson's disease?

  2005cites this paper
• Alpha-melanocyte-stimulating hormone in normal human physiology and disease states.

  2000cites this paper
• Improvement of body image perception in Parkinson's disease by treatment with weak electromagnetic fields.

  1995cites this paper
• Reversal of visuospatial deficit on the Clock Drawing Test in Parkinson's disease by treatment with weak electromagnetic fields.

  1995cites this paper
• Weak electromagnetic fields reverse visuospatial hemi-inattention in Parkinson's disease.

  1995cites this paper
• Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

  1993cites this paper
• alpha-Melanocyte stimulating hormone in the modulation of host reactions.

  1993cites this paper
• Nocturnal plasma melatonin and alpha-melanocyte stimulating hormone levels during exacerbation of multiple sclerosis.

  1992cites this paper
• Risk factors for neuroleptic-induced movement disorders.

  1991cites this paper
• Pineal melatonin functions: possible relevance to Parkinson's disease.

  1990cites this paper
• Melanocyte-stimulating hormone and persistent tardive dyskinesia: a hypothesis.

  1990cites this paper
• The relationship of negative schizophrenia to parkinsonism.

  1990cites this paper
• MIF-induced augmentation of melatonin functions: possible relevance to mechanisms of action of MIF-1 in movement disorders.

  1990cites this paper
• Topographic subtypes of tardive dyskinesia: relationship to seborrhea.

  1990cites this paper
• Melanocyte-stimulating hormone in tardive dyskinesia.

  1989cites this paper
• Autoimmune mechanisms in Parkinson's disease.

  1989cites this paper